To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Nanoform and AstraZeneca Initiate Technology Evaluation
Nanoform has announced the initiation of a technology evaluation of Nanoform’s Proprietary CESS(R) Technology across a range of AstraZeneca’s proprietary pharmaceutical products.
The initiation of this study is to assess the added value that Nanoform’s proprietary technology could deliver across the pharmaceutical value chain.
Commenting on the agreement, Edward Hæggström, CEO of Nanoform said:
“We have always believed that our technology has significant value to offer the Pharma industry, particularly in reducing clinical attrition rates by nanonizationTM to increase dissolution rates of poorly soluble APIs and overcome significant bioavailability challenges, as evidenced by the work conducted between us and our pharmaceutical partners.
Producing tailored nanoparticles <200nm from solution, in a controlled and reproducible manner, with good yield and without the need for excipients is highly challenging to do by current pharmaceutical manufacturing techniques or processes."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
